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Objectives:Despite advances in endovascular therapies, critical limb ischemia (CLI) continues to be associated with highmorbidity
and mortality. Patients without direct revascularization options have the worst outcomes. We sought to explore the feasibility of
conducting a definitive trial of a bone marrow-derived cellular therapy for CLI in this “no option” population.
Methods: A pilot, multicenter, prospective, randomized, double-blind, placebo-controlled trial for “no option” CLI
patients was performed. The therapy consisted of bone marrow aspirate concentrate (BMAC), prepared using a point of
service centrifugation technique and injected percutaneously in 40 injections to the affected limb. Patients were
randomized to BMAC or sham injections (dilute blood). We are reporting the 12-week data.
Results: Forty-eightpatientswere enrolled.Themeanagewas69.5 years (range, 42-93years).Males predominated (68%).Diabetes
was present in 50%. Tissue loss (Rutherford 5)was present in 30 patients (62.5%), and 18 (37.5%) had rest painwithout tissue loss
(Rutherford 4). Patientswere deemed unsuitable for conventional revascularization based onmultiple prior failed revascularization
efforts (24 [50%]), poor distal targets (43 [89.6%]), andmedical risk (six [12.5%]). Thirty-four patients were treated with BMAC
and 14 with sham injections. There were no adverse events attributed to the injections. Renal function was not affected. Effective
blindingwas confirmed;blinding indexof61%to85%.Subjective andobjectiveoutcomemeasureswere effectivelyobtainedwith the
exception of treadmill walking times, which could only be obtained at baseline and follow-up in 15 of 48 subjects. This pilot study
was not powered to demonstrate statistical significance but did demonstrate favorable trends for BMAC versus control in major
amputations (17.6% vs 28.6%), improved pain (44% vs 25%), improved ankle brachial index (ABI; 32.4% vs 7.1%), improved
Rutherford classification (35.3% vs 14.3%), and quality-of-life scoring better for BMAC in six of eight domains.
Conclusions: In this multicenter, randomized, double-blind, placebo-controlled trial of autologous bone marrow cell
therapy for CLI, the therapy was well tolerated without significant adverse events. The BMAC group demonstrated
trends toward improvement in amputation, pain, quality of life, Rutherford classification, and ABI when compared with
controls. This pilot allowed us to identify several areas for improvement for future trials and CLI studies. These
recommendations include elimination of treadmill testing, stratification by Rutherford class, and more liberal inclusion
of patients with renal insufficiency. Our strongest recommendation is that CLI studies that include Rutherford 4 patients
should incorporate a composite endpoint reflecting pain and quality of life. ( J Vasc Surg 2011;54:1650-8.)
t
C
d
t
Y
m
t
c
c
a
s
r
i
r
s
a
s
p
sCritical limb ischemia (CLI), has a 1-year mortality of
approximately 25%, with major limb amputations afflicting
another 30%.1 Surgical and endovascular recanalization
improves perfusion, pain, quality of life, and limb preserva-
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1650ion in the majority of patients. However, 25% to 40% of
LI patients are not candidates for revascularization.1-3
In 1997, Asahara identified a class of bone marrow-
erived, circulating endothelial progenitor cells that con-
ribute to angiogenesis in ischemic tissue,4 while Tateishi-
uyama was the first to report the use of autologous bone
arrow-derived cells (BMDCs) to treat CLI in a human
rial. They used patients with bilateral ischemia as their own
ontrols and compared bone marrow-derived mononuclear
ells (BMDMC) versus saline or peripherally derived cells
nd showed improvement in objective and subjective mea-
ures of perfusion.5 Since then, numerous studies have
eported the safety and feasibility of autologous BMDMCs
n CLI. The majority of these were case series,6-27 with few
andomized, controlled trials.5,28-33 While there have been a
mall number of blinded studies in the cardiac literature,34-37 Lu
nd colleagues provided the first well-controlled and blinded
tudy in diabetic patients with CLI and ulcers. This study of 41
atients found bone marrow mesenchymal stem cells to be
uperior to mononuclear cells or normal saline in improving
erfusion and ulcer healing.33 Initial studies of cellular thera-
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Volume 54, Number 6 Iafrati et al 1651pies utilized time- and resource-intensive Ficoll density gradi-
ent separation techniques to isolate the target cells, with or
without subsequent cell expansion, whereas several recent
reports, including this study utilized automated point of ser-
vice centrifugation techniques.6,17,32
Robust trials for cellular therapy in CLI are complicated
by severe comorbidities, challenges of blinding, inclusion
criteria, and choice of outcome measures. In order to access
these trial-related issues as well as the safety of cellular
therapy for CLI, we undertook a Food and Drug Admin-
istration (FDA)-cleared pilot study.
METHODS
Patients. Patients had chronic CLI, including rest pain
(Rutherford class 4 [R4]) or mild-to-moderate tissue loss
(Rutherford class 5 [R5]) and were not candidates for surgical
or endovascular revascularization. Patients were determined
to be poor candidates for conventional therapy based on
anatomic (target vessel, conduit, failed bypasses, long or cal-
cified occlusions) or physiological considerations, attested to
by two vascular surgeons. Hemodynamic parameters included
one of the following: ankle pressure 50 mm Hg or ABI
0.4; toe pressure 40 mm Hg or toe brachial index (TBI)
0.4; or tissue oxygen concentration (TcPO2) 20 mm Hg
on room air. Patients with noncompressible ankle brachial
indices (ABIs) were evaluated based on TBI or TcPO2.
Exclusion criteria included: severe tissue loss (Ruther-
ford class 6); creatinine 2.0 mg/dL or dialysis; ABI  0;
uncorrected iliac disease in the index limb; active infection;
active malignancy; major cardiovascular procedure or myo-
cardial infarction within 3 months; stroke within 6 months;
bone marrow or hematologic disorders; uncontrolled dia-
betes (HgbA1C  10%); or hyperbaric oxygen therapy
within 30 days.
Subjects underwent cancer (prostate, cervical, breast,
lung, colon) and ophthalmologic screenings. The institutional
review boards of all participating sites approved the study.
METHODS
The study procedure involved aspiration and process-
ing of bone marrow and injection of BMAC or sham
injectate into the study limb. Procedures were carried out
under conscious sedation. Local anesthesia was utilized for
the bone marrow harvest. For patients randomized to cell
therapy, 120 mL of marrow was withdrawn from each iliac
crest. For control patients, the iliac crest was punctured
bilaterally and 2 mL withdrawn to maintain blinding. Mar-
row aspirate was processed using the SmartPReP2 Bone
Marrow Aspirate Concentrate system (Harvest Technolo-
gies, Plymouth, Mass). This point-of-care system consists
of an automated centrifuge that concentrates marrow by a
gradient centrifugation method. The processing was car-
ried out in the operating room (14 minutes). Aliquots (2
mL) of BMA and BMAC were collected and later analyzed
for cell counts. The concentrate (40 mL) was loaded into
syringes for injection into the index limb. Ten milliliters of
peripheral blood was withdrawn from all patients at the
time of intravenous placement; for control subjects this was ciluted 3:1 and presented in a syringe for intramuscular
njection. Medial and or anterior linear injection patterns
n the lower leg were selected based on preoperative imag-
ng to replicate a “biologic bypass.” Under ultrasound
uidance, 40 1-mL intramuscular injections, spaced 1 to 2
m apart, 5 to 10 mm from the popliteal, tibial, and/or
edal arteries, extended distally to the area of tissue loss or
rterial reconstitution.
Randomization and blinding. Patients were ran-
omized 2:1, investigational treatment or placebo using
lock stratification by investigational site, diabetes, and
enal function (creatinine clearance 40 mg/dL). Forty-
ight patients were enrolled: 34 cell therapy, 14 placebo.
his study was FDA approved as a pilot and not powered
or statistical significance. Study group assignment was
evealed, to the individual performing the bone marrow
spiration, in the operating room after prepping and drap-
ng. Bilateral iliac punctures were performed. Treatment
atients had 240 mL marrow aspirated versus 2 mL in
ontrols. Following centrifugation of the aspirate (treat-
ent group) or sham operation of the centrifuge (control),
he unblinded physician and study coordinator left the
rocedure room and the blinded vascular surgeon and
oordinator entered. The surgeon was presented with four
yringes for injection without knowing their contents. The
ham injectate has color and consistence indistinguishable
rom BMAC, and, like BMAC, will clot if inadvertently
ripped in the field. Effectiveness of blinding was assessed
y querying the patients and clinicians after the procedure
nd at the conclusion of the study. Although an interim
nalysis was performed at 3 months per protocol, blinding
ill be maintained during the 5-year follow-up.
Follow-up and outcome measurements. Patients
ere evaluated at 1, 4, 8, and 12 weeks postprocedure.
ollow-up for 5 years is planned. Evaluation included sub-
ective and objective measures of clinical, hemodynamic,
nd functional outcomes. Clinical outcomes included am-
utation, Rutherford classification, visual analog pain scale,
nd walking distance. Functional outcome was evaluated
sing the Rand-36 questionnaire. Hemodynamic outcome
as evaluated by ABI and TcPO2. Laboratory monitoring
f hematology and blood chemistries was performed. Ret-
nal examination was performed by an ophthalmologist at
aseline and 3 months in diabetics.
ESULTS
Patient baseline characteristics are presented in Table I.
ll randomized patients received the prescribed treatment
nd presented for 1-week follow-up. Four subjects missed
heir 12-week visit but were available for subsequent eval-
ation, and thus their survival and amputation were in-
luded although hemodynamic and questionnaire data
ere missing. Missing data were handled using the last
bservation carried forward (LOCF) method.
rocedure
Marrow aspiration, processing, and injections were ac-
omplished in the operating room at a single visit. Patients
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December 20111652 Iafrati et altolerated the procedure well, transient deep sedation was
utilized to facilitate the injections, and none required intuba-
tion. There were no complications on the day of treatment.
The mean number of nucleated cells injected per patient was
3.23  109 cells (range, 0.88-7.44  109). Cell counts did
not correlate with age, diabetes, or outcome but did correlate
with Hct.
Safety and adverse events
There were no deaths or severe unexpected adverse
events during this 3-month reporting period. Bone marrow
aspiration was well tolerated with no complications. He-
matocrit decreased by 2.6% in the BMAC group (Table II),
and no patient was transfused. Injections were well toler-
ated with no infections, ulceration, or persistent pain. One
control patient experienced edema of the index limb fol-
lowing injection of placebo, without venous thrombosis.
Table I. Baseline characteristics of enrolled patients
Bone marro
Patients
Age (years) 72.5
Male 23
Race
Asian 5
Black/African American 4
Caucasian 25
Tobacco use
Never used 9
Previous user 19
Current user 6
Diabetes mellitus
Type 1 diabetes 1
Type 2 diabetes 17
Renal insufficiency (Cr clearance 40 mg/dL) 3
Cardiac disease
Angina 4
Myocardial infarction 11
Congestive heart failure 7
Coronary revascularization
Coronary artery bypass 11
Coronary angioplasty 5
Rutherford class
Rutherford 4 11
Rutherford 5 23
Ankle brachial index 0.46
Previous amputation (contralateral)
Major amputation 7
Minor amputation 6
Previous lower extremity revascularization
Surgical bypass 23
Angioplasty 8
Stent 5
Atherectomy 2
Reason for no option status
Failed revascularization 18
Anatomic poor candidate 31
Medical high risk 5
Medication
Cholesterol lowering agent 24
Beta blocker 15
Antiplatelet agent 28Muscle injury due to the intramuscular injections (rhabdo- tyolysis) was not observed clinically or chemically (creatine
hosphokinase [CPK]). The mean CPK for the cell therapy
roup decreased by 31% 1 week after treatment and in-
reased by 7% in the controls. Renal function remained
table in both groups (Table II).
No patient demonstrated inappropriate angiogene-
is. Ophthalmologic examinations at screening demon-
trated baseline proliferative retinopathy in four patients,
ut there were no cases of worsened or new retinopathy.
here were no clinically evident cases of new or recurrent
alignancy.
fficacy and outcomes
Amputations. There were 10 major amputations dur-
ng the 3-month period (Table III). All major amputations
ccurred in patients who were Rutherford 5 at screening.
mong patients who were R5 at baseline, major amputa-
irate concentrate Control Total
14 48
-93) 65.7 (52-85) 69.5 (42-93)
.6%) 9 (64.3%) 32 (66.7%)
.7%) 1 (7.1%) 6 (12.5%)
.8%) 6 (42.9%) 10 (20.8%)
.5%) 7 (50.0%) 32 (66.7%)
.5%) 6 (42.9%) 15 (31.3%)
.9%) 8 (57.1%) 27 (56.3%)
.6%) 0 (0%) 6 (12.5%)
%) 1 (7.1%) 2 (4.2%)
.0%) 5 (35.7%) 22 (45.8%)
%) 1 (7.1%) 4 (8.3%)
.8%) 3 (21.4%) 7 (14.6%)
.4%) 2 (14.3%) 13 (27.1%)
.6%) 4 (28.6%) 11 (22.9%)
.4%) 2 (14.3%) 13 (27.1%)
.7%) 6 (42.9%) 11 (22.9%)
.4%) 7 (50.0%) 18 (37.5%)
.6%) 7 (50.0%) 30 (62.5%)
3-1.23) 0.40 (0.17-0.74) 0.44 (0.13-1.23)
.6%) 1 (7.1%) 8 (16.7%)
.6%) 2 (14.3%) 8 (16.7%)
.6%) 8 (57.1%) 31 (64.6%)
.5%) 7 (50.0%) 15 (31.2%)
.7%) 6 (42.9%) 11 (22.9%)
%) 4 (28.6%) 6 (12.5%)
.9%) 6 (42.9%) 24 (50.0%)
.2%) 12 (85.7%) 43 (89.6%)
.7%) 1 (7.1%) 6 (12.5%)
.6%) 11 (78.6%) 35 (72.9%)
.1%) 5 (35.7%) 20 (41.7%)
.3%) 14 (100%) 42 (87.5%)w asp
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Volume 54, Number 6 Iafrati et al 1653(P  .18). Minor amputations were performed in seven
patients (four BMAC, three controls). Three minor ampu-
tations were subsequently revised to major amputations
(one BMAC, two controls).
Rutherford class. All patients were Rutherford 4 or 5
at screening. Improvement in Rutherford score required
complete wound healing (R5 ¡ R4) or resolution of rest
pain (R4¡R3, 2, 1), whereas the development of rest pain
or irretrievable tissue loss (R6) represented a worsening of
the score. All major amputations were recorded as wors-
ened Rutherford score (Table IV).
Pain. Pain was assessed using a 100-mm VAS. An abso-
lute change of 30 mm on the VAS from baseline was required
to denote either improvement or worsening. Table V reports
these data for patients without major amputation.
Walking distance. We endeavored to evaluate walking
distance by treadmill testing. However, because of pain or
associated comorbidities, many did not complete or even
attempt the test. At screening, 21 patients did not complete
the baseline test, and of those who did, another six were
Table II. Periprocedure laboratory values: Mean (range)
Bone mar
Hematocrit (%)
Screening 35
Day 7 33
Mean change 2
Creatine phosphokinase (u/L)
Screening 103
Day 7 71
Mean change 33
Serum creatinine (mg/dL)
Screening 1
Day 7 1
Mean change 0
Table III. Major amputations (3 month): Bone marrow a
Amputations
All patients 10
Bone marrow aspirate concentrate 6
Control 4
Major amputations are above- or below-knee amputations.
aP calculated using Fisher’s exact test, two-tailed.
Table IV. Change in Rutherford classification
Improved
Not
improved
%
Improved
P
valuea
Bone marrow aspirate
concentrate
12 22 35.3% .18
Control 2 12 14.3%
R4 10 8 55.6% .003
R5 4 26 13.3%
R4, Ischemic rest pain; R5, limited tissue loss.
aP values calculated using Fisher’s exact test, two-tailed.unable to complete follow-up. PQuality of life. Quality of life was measured using the
and-36 questionnaire at baseline and 3 months. We cal-
ulated the change in individual patients’ scores (Table VI).
hile BMAC patients demonstrated improvements com-
ared with controls in six of the eight domains, only the
hysical Function domain approached statistical signifi-
ance (P  .06).
ABI and TcPO2. TcPO2 at the transmetatarsal level
rended toward improvement in BMAC (12 increasing to
5 mm Hg) versus controls (15 increasing to 17 mm Hg;
spirate concentrate Control
7.7-42.7) 36.2 (28.7-42.9)
4.5-42.0) 36.0 (30.0-44.0)
7.0-2.6) 0.1 (5.8-4.5)
1.0-490.0) 99.0 (37.0-234.0)
0.0-281.0) 107.0 (5.2-237.0)
430.0-77.0) 5.5 (50.0-64.0)
.6-2.0) 1.0 (0.7-1.2)
.5-1.8) 1.1 (0.7-1.5)
0.1-0.4) 0.1 (0.1-0.4)
te concentrate versus control
Total % Amputations P valuea
48 20.8%
34 17.6% 0.448
14 28.6%
able V. Outcome measures (pain and composite)
Bone marrow
aspirate
concentrate Control P
ain .54
Improved 11/25 (44.0%) 2/8 (25.0%)
Stable 12/25 (48.0%) 6/8 (75.0%)
Worsened 2/25 (8.0%) 0/8 (0%)
omposite
endpoint
.11
Success 17/34 (50%) 3/14 (21.4%)
Failure 17/34 (50%) 11/14 (78.6%)
ain is self-reported using a 100-mm visual analog scale.
hanges at 12 weeks compared to baseline of 30 mm are reported as
improved” or “worsened.”
hanges of 30 mm are “stable.”
omposite outcome: to be a “success,” a subject must: A, be alive; B, be
ithout a major amputation on the index limb; C, have not worsened in
utherford classification or visual analog pain scale; and D, have improved in
ither Rutherford classification or visual analog pain scale. Subjects not
eeting all of the criteria were classified as failures.row a
.9 (2
.4 (2
.6 (
.8 (1
.3 (1
.9 (
.1 (0
.1 (0spira NS). Only 28 of 48 patients had evaluable baseline and
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December 20111654 Iafrati et al12-week ABI recordings as a result of amputation, missed
testing, or noncompressibility. Analysis of the evaluable paired
data demonstrated an improvement in mean ABI for BMAC
of 0.12 (n  22), whereas controls decreased 0.17 (n 
6; P .13). A priori, we defined a significant change in ABI
as a change 0.1. Patients were “improved” if their ABI
increased by 0.1, while they were “not improved” if the
ABI increased by 0.1, they had a major amputation, or
did not have evaluable data. Noncompressible ABIs (1.1)
were excluded. TBIs were requested when the ABI  1.1;
however, small numbers of these cases preclude analysis
(Table VII).
Blinding
Patients and investigators (except for the bone marrow
aspirating team) were blinded. To evaluate blinding, pa-
tients and investigators were asked, on the day of treatment,
to identify which treatment arm they thought the patient
was assigned. The blinding index equals percent incorrect
guesses  percent undecided guesses.38 Blinding indexes
50% suggest successful blinding. The blinding index for
subjects and investigators in this study ranged from 61.5%
to 84.6%, indicating successful blinding (Table VIII).
DISCUSSION
Role of cell therapy. A recent study examining tissue
in patients treated with bone marrow-derived cells has
Table VI. Quality of life (Rand-36)
Bone marrow
aspirate
concentrate Control Pa
General health 2.46 2.2 .45
Physical function 4.58 15.3 .06
Role physical 10.77 2 .24
Role emotional 6.73 15 .51
Vitality 4.5 0.4 .44
Mental health 5.12 9.2 .47
Social function 6.35 4.3 .15
Bodily pain 8.96 1.6 .35
Rand-36 instrument utilized with permission.
Data are the means for changes in individuals who completed the question-
naire at baseline and 12-week follow-up.
aP calculated from two-sample Wilcoxon (nonparametric) test.
Table VII. Change in ankle-brachial index
Improved
Not
improved Total
%
Improved Pa
Bone marrow
aspirate
concentrate 11 23 34 32.4% .08
Control 1 13 14 7.1%
Increases in ankle-brachial index that are 0.1 are considered “improved.”
Patients who increased by less than 0.1, worsened, had major amputations,
or did not have follow-up studies were considered “not improved.”
aP value calculated using Fisher’s exact test, two-tailed.demonstrated growth of small blood vessels in humans with gLI.39 Our pilot study supports the potential of bone
arrow-derived cells as a regenerative medical intervention
or CLI.
Since Tateishi-Yuyama et al published their work de-
cribing the first use of cell therapy in CLI in 2002, reports
ave included over 1000 treated patients. However, the
ajority of these studies are case series. While early work on
ell therapy for CLI has demonstrated its feasibility, it will
ot be accepted as a proven therapy until it has succeeded in
obust, randomized, and blinded studies.
The point-of-care system (Harvest SmartPReP2), which
rocessed cell concentrate in this study, has been used in
ther clinical trials for both cardiac40,41 and vascular6,17,32
ndications. The system demonstrated several advantages:
he centrifuge did not require a separate laboratory techni-
ian for operation; processing was done within 15 minutes;
nd samples did not leave the procedure room. Further-
ore, the system was capable of achieving mean cell counts
f 3.23  109 from 240 mL of marrow aspirate, numbers
hat are comparable to 1.6 109 achieved by the Tateishi-
uyama (Ficoll) protocol that requires 500 mL aspirate.
he smaller volume of marrow leads to shorter marrow
arvesting times, less anesthesia risk, and less anemia.
This randomized, double-blinded controlled, pilot
tudy of cell therapy in CLI, although not powered to prove
fficacy, showed cell therapy to be feasible and safe in
o-option patients. Furthermore, we were able to establish
he utility of the study design as well as areas for improve-
ent.
Study design. This study included rest pain (R4) and
issue loss (R5) patients. Although the designation of rest
ain is based on subjective complaints, the accompanying
emodynamic inclusion criteria assured the severity of vas-
ular disease at baseline. While limb salvage with a limited
mputation of toes or forefoot was an acceptable outcome
able VIII. Assessment of blinding
ubject’s guess
Actual treatment
Bone marrow
aspirate concentrate
(n  32)
Control
(n  13)
one marrow aspirate
concentrate 9 (28.1%) 4 (30.8%)
lacebo 0 (0%) 2 (15.4%)
ndecided 23 (71.9%) 7 (53.8%)
linding index 71.9% 84.6%
nvestigator’s guess
Bone marrow aspirate
concentrate
8 (25.0%) 4 (30.8%)
Placebo 4 (12.5%) 5 (38.5%)
Undecided 20 (62.5%) 4 (30.8%)
Blinding index 75.0% 61.5%
atients and investigators were asked prior to discharge on the day of
reatment to identify which treatment arm they thought the patient was
ssigned.
linding index equals (percent [incorrect]  percent [undecided]).
hen blinding exceeds 50%, subjects have been successfully blinded.40oal, we excluded patients with extensive mid foot or hind
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Volume 54, Number 6 Iafrati et al 1655foot necrosis (R6) for whom major amputation was un-
avoidable.
Important outcome measures for any study of CLI
include amputation, pain, and quality of life. While ampu-
tation is objective and VAS is well established, both mea-
sures could be influenced by knowledge of treatment group
assignment. For instance, a patient or his or her physician
who believes that an active treatment was administered
might tolerate severe pain or stable tissue loss for a longer
period of time before committing to amputation. Likewise,
self-reporting of pain or quality of life could be influenced.
Therefore, blinding the investigator and patient is key. In
this study, randomization was managed centrally ensuring
strict adherence to protocol. Blinding was maintained by
several processes: (1) separating the unblinded physician
and research coordinator, who performed the bone marrow
harvesting, from the vascular surgeon and coordinator,
who carried out injections and subsequent care; (2) per-
forming marrow punctures on both treatment and control
patients; (3) operating the centrifuge for both groups of
patients. Placebo injections were diluted peripheral blood,
which closely simulated BMAC. Assessment of both patient
and investigator demonstrated successful blinding. The
blinding procedures presented here provide a robust ap-
proach that may be incorporated in future cell therapy trials
in CLI.
Safety. Despite a high reported baseline amputation
and death rate in this population, there were no deaths and
no unanticipated major adverse events in either the treat-
ment or control groups. There were no instances of clini-
cally relevant anemia, rhabdomyolysis, or kidney injury
associated with therapy.
Proliferative retinopathy is a serious issue for diabetics,
and it is appropriate to ask whether a therapy designed to
promote neovascularization might worsen this condition.
To date, there has been no indication that cellular therapies
worsen retinopathy.21 Rather, some have postulated that
cellular therapy may mitigate retinopathy.42,43 Similarly,
there is speculation that BMDCs may contribute to cancer
development by supporting tumor angiogenesis.44,45 How-
ever, Wickersheim showed that bone marrow-derived endo-
thelial progenitor cells do not contribute to tumor endothe-
lium in either primary or metastatic tumors.46 A review of
the literature demonstrates only a single study in which the
cancer rate in stem cell patients was higher than expected.13
However, in that series, all patients received granulocyte-
colony stimulating factors (G-CSF), which may have played
a role in the unexpectedly high cancer rate. In our pilot, no
exogenous growth factors were administered, and no ma-
lignancies were diagnosed.
Efficacy and outcome measures. Given the histori-
cally high risk of death and amputation among patients
with unreconstructable CLI, the use of amputation-free
survival (AFS) as an objective primary outcome measure has
merit. There is, however, a subjective component to decid-
ing when an amputation is necessary, and maintenance of
blinding is vital to avoid such bias. Variations in surgeons’
threshold for amputation was addressed by requiring a tecond opinion for amputations, while regional or hospital
ifferences were mitigated by including the site as a strati-
cation variable. The pilot study was not powered to show
tatistical significance. However, nearly every outcome
easure favored the BMAC group over the controls: major
mputations (17.6% vs 28.6%), improved pain (44% vs
5%), improved ABIs (32.4% vs 7.1%), improved Ruther-
ord classification (35.3% vs 14.3%), and quality-of-life scoring
etter for BMAC in six of eight domains. Using these pilot
ata as assumptions in a power calculation, we estimate
hat a pivotal study with similar criteria, using AFS as a
rimary outcome measure, would require at least 210
atients to achieve a power of 0.8 for P  .05.
Composite outcome. Limb preservation and survival
AFS) are clearly the sine qua non of a successful CLI
ntervention. However, AFS fails to consider pain, limited
obility, and other factors that impact quality of life.
lthough the risk of amputation or death in CLI patients
ith the tissue loss is daunting in the near term, patients
ith rest pain have a more indolent course wherein quality
f life is important. In this pilot, there were no amputations
n R4 patients in the first 12 weeks. Thus, for studies which
nclude R4 and R5 patients, we believe that AFS is not an
ppropriate primary stand-alone outcome measure. There-
ore, we constructed a composite outcome which accounts
or the goals of therapy that patients and physicians value.
n this proposed metric, to be classified as a success, a
ubject must: (1) be alive; (2) without a major amputation
n the index limb; and (3) have improved in either Ruth-
rford classification or VAS pain scale, while not deteriorat-
ng in either. Subjects meeting all of these criteria were
lassified as successes. By this measure, success was achieved
n 17 of 34 (50%) BMAC versus three of 14 (21.4%) control
atients (P .11). In this pilot study, the composite results
re similar to the AFS; however, it is notable that most
ubjects were R5 at enrollment. If future studies enrolled a
igher proportion of R4 patients, we believe that AFS
ould perform poorly. Therefore, a composite outcome
easure such as the one proposed should be validated in
uture studies, as it reflects our therapeutic goals.
Rutherford classification. The Rutherford classifica-
ion system distinguishes rest pain from tissue loss; how-
ver, clinical trials often group CLI patients together. Yet
issue loss is biologically different from rest pain. Recently,
esearchers have begun distinguishing differences in out-
omes within the CLI population. In a study of 2240
atients with peripheral arterial disease, Taylor et al found
hat outcomes following revascularization varied with de-
ree of disease at presentation. They state, “For every
utcome measure, patients with claudication significantly
utperformed those with ischemic rest pain, and patients
ith rest pain significantly outperformed those with isch-
mic tissue loss.”47 Valid data in CLI studies are therefore
redicated on an equal distribution of disease severity be-
ween treatment groups.
Treadmill testing. Patients were scheduled to un-
ergo treadmill testing at screening and follow-up. Unfor-
unately, 27 of 48 patients did not complete the treadmill
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wounds, or unsteadiness. For the pivotal trial, we will
eliminate the treadmill test and replace it by a simple
question of whether or not the patient is ambulatory (with
or without assistance) or nonambulatory. This question-
naire approach has been supported by several recent publi-
cations.48-50
Creatinine cut-off. Chronic renal insufficiency is a
risk factor for death and amputation in CLI.51-53 Although
this population may have the most to gain from innovative
therapies given their poor response to conventional modal-
ities, the risk of failure is onerous, and therefore, dialysis
patients are not appropriate for initial testing of biological
therapies in CLI. However, since nearly 25% of patients
with chronic renal insufficiency also have peripheral arterial
disease,54 requiring normal renal function in clinical trials
would not reflect the general target population. Further-
more, patients with more severe renal insufficiency are less
likely to be candidates for surgical or endovascular therapy.
This pilot study required a creatinine2.0, which resulted
in the exclusion of many otherwise suitable candidates.
Since we did not demonstrate any adverse effect on renal
function nor change in outcome, we support a more liberal
threshold for future studies, which will better reflect the
CLI population as a whole.
Potential weaknesses of the study. In this trial, we
did not aim for a particular cell count. However, analysis of
our BMAC demonstrated cell yields equivalent or superior
to those achieved in prior studies. The eight-fold range in
cell counts in this protocol suggests that future refinements
in technique might include individualizing the aspirate
volume based on preoperative indicators of cellular yield
such as Hct or C-reactive protein or the use of repeat
treatments if yields are low. This protocol embraces a
point-of-care technique for marrow processing, which is
fast and easy. By not requiring dedicated laboratory facili-
ties or personnel, this protocol may be feasible for a wide
range of clinicians and patients.
CONCLUSION
In this multicenter, randomized, double-blind con-
trolled trial of autologous bone marrow-derived cell ther-
apy for CLI, the therapy was well tolerated without signif-
icant adverse events associated with the procedure during
3-month follow-up. The cell therapy group demonstrated
trends toward improvement in amputation rate, pain, qual-
ity of life, Rutherford classification, TcPO2, and ABI when
compared with controls. This pilot identified several areas
for improvement in future trials. Recommendations in-
clude elimination of treadmill testing, stratification by
Rutherford class, and more liberal creatinine cut off. Our
strongest recommendation is that CLI studies that include
Rutherford 4 patients, stratify according to disease severity,
and incorporate a composite endpoint reflecting pain and
quality of life.
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